999.0000 -4.80 (-0.48%)
NSE Aug 10, 2026 15:31 PM
Volume: 151.0K
 

999.00
-0.48%
Geojit BNP Paribas
The company reiterated its FY28 revenue target of $400 million, supported by a pipeline of 60+ pending low-competition U.S. product launches. Management also remains optimistic about other regulated markets, where portfolio expansion and new customer additions are expected to drive stronger growth and gradually scale revenues to levels comparable to the U.S. business....
Strides Pharma Science Ltd. is trading below its 30 day SMA of 1056.6
More from Strides Pharma Science Ltd.
Recommended